All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2021; the latest 2026-04-30.
From the record
Pomdoctor Limited's filings since 2021 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2026-04-30) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+14.5% a year over 3 filed years; profitable in 0 of 3.
From the record
Pomdoctor Limited's 3 filed years say what it did: revenue went from CNY 305 million in fiscal 2023 to CNY 400 million in fiscal 2025, up 14.5% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 0 of 3 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 2.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Pomdoctor Limited's shareholder treatment is put at 2.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 21% of 12 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 547%: owes 547¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Pomdoctor Limited's shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 49 cents per dollar of everything the company owns. Leverage: it owed about 547 cents per dollar of assets, and net share issuance: its share count grew 53.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 46% of 12 in its family; net margin -32.7%.
From the record
Pomdoctor Limited's standing among 12 graded names in its industry family: revenue of CNY 400 million in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of -32.7% ranks in the bottom 21%; revenue growth of 14.5% a year over the last 2 filed years ranks in the top 29% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 4.5/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Pomdoctor Limited's leadership is put at 4.5 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-31 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 8 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 18% of 12 in its family for room to expand.
From the record
Pomdoctor Limited's room to grow, from the newest filed statements (fiscal 2025): cash of CNY 10 million against debt of CNY 82 million leaves -67.2% of its assets as net cash, bottom 4% of its family; cash from operations less capital spending is -37.4% of revenue (bottom 13%); a gross margin of 13.1% (bottom 32%); research spending of 3.2% of revenue (bottom 25%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 24% of 11 in its family for growth drivers.
From the record
Pomdoctor Limited's growth drivers, from the filed years to fiscal 2025: revenue grew 14.5% a year over the last three filed years against 14.5% over all 3, speeding up (top 18% of its family); the newest year grew 16.8% (top 23%); research spending grew 95.3% a year (top 50%); capital spending grew 199.9% a year (top 5%) (its annual reports). Pomdoctor Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 4.8/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Pomdoctor Limited's expectations vs reality is put at 4.8 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 10 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made